BlackRock Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | $1.64M | Sell |
43,922
-235,204
| -84% | -$8.8M | ﹤0.01% | 1550 |
|
|
2016
Q3 | $18.9M | Sell |
279,126
-93,542
| -25% | -$6.34M | 0.02% | 536 |
|
|
2016
Q2 | $20.7M | Buy |
372,668
+78,149
| +27% | +$4.34M | 0.02% | 507 |
|
|
2016
Q1 | $18.5M | Buy |
294,519
+114,990
| +64% | +$7.22M | 0.02% | 549 |
|
|
2015
Q4 | $16.9M | Buy |
179,529
+13,612
| +8% | +$1.28M | 0.02% | 598 |
|
|
2015
Q3 | $13.3M | Buy |
165,917
+6,158
| +4% | +$495K | 0.01% | 650 |
|
|
2015
Q2 | $19.2M | Buy |
159,759
+13,849
| +9% | +$1.66M | 0.02% | 527 |
|
|
2015
Q1 | $15.2M | Buy |
145,910
+136,178
| +1,399% | +$14.2M | 0.02% | 638 |
|
|
2014
Q4 | $944K | Hold |
9,732
| – | – | ﹤0.01% | 1507 |
|
|
2014
Q3 | $760K | Sell |
9,732
-32,035
| -77% | -$2.5M | ﹤0.01% | 1600 |
|
|
2014
Q2 | $2.64M | Sell |
41,767
-49,435
| -54% | -$3.12M | ﹤0.01% | 1077 |
|
|
2014
Q1 | $6.12M | Buy |
91,202
+54,503
| +149% | +$3.66M | 0.01% | 909 |
|
|
2013
Q4 | $2.36M | Sell |
36,699
-1,059,905
| -97% | -$68.2M | ﹤0.01% | 1116 |
|
|
2013
Q3 | $70.2M | Sell |
1,096,604
-73,347
| -6% | -$4.69M | 0.07% | 272 |
|
|
2013
Q2 | $36.3M | Buy |
+1,169,951
| New | +$36.3M | 0.04% | 375 |
|